In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

Pseudomonas aeruginosa global clones associated with multidrug-resistant (MDR) and
extensively drug-resistant (XDR) phenotypes, denominated high-risk clones, are a growing …

P. aeruginosa is classified as a priority one pathogen by the World Health Organisation, and
new drugs are urgently needed, due to the emergence of multidrug-resistant (MDR) strains …

The antibacterial agents currently in clinical development are predominantly derivatives of
well-established antibiotic classes and were selected to address the class-specific …

Pseudomonas aeruginosa is a major opportunistic pathogen, causing a wide range of acute
and chronic infections. β-lactam antibiotics including penicillins, carbapenems …

One of the most striking features of Pseudomonas aeruginosa is its outstanding capacity for
developing antimicrobial resistance to nearly all available antipseudomonal agents through …

As a class, the b-lactams are the most commonly prescribed and clinically dependable
antimicrobials in the United States, representing more than 65% of injected antibiotic …

Genomics offered the promise of transforming antibiotic discovery by revealing many new
essential genes as good targets, but the results fell short of the promise. While numerous …

The major human bacterial pathogen Pseudomonas aeruginosa causes multidrug-resistant
infections in people with underlying immunodeficiencies or structural lung diseases such as …

Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in
combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and …